Could Oral Biosimilars of Humira and Embrel Disrupt the Biologics Market?

Companies developing oral biosimilar versions of injectable biologic drugs may have a better chance of capturing market share, according to a study conducted by research firm Frost & Sullivan and California-based biopharmaceutical company Rani Therapeutics. The collaborators say that their findings could not only help oral biosimilars gain momentum in the biologics market, but they could also help pharmaceutical companies protect their IP by developing their own oral version of large molecule biologics.